Atlas of Psychiatric PharmacotherapyCRC Press, 13 jan 2006 - 288 pagina's The second edition of this exceptional book provides a comprehensive understanding of the mechanisms of action involved in psychiatric pharmacotherapy. Using imaginative colourful double-page spreads, this exceptional book presents state-of-the-art information on all the basic principles of psychiatric pharmacotherapy, abused substances, drug inter |
Vanuit het boek
Resultaten 1-5 van 56
Pagina v
... inducing 'non-psychiatric' symptoms 1.14 Drug pharmacokinetics Main pathways of drug metabolism 1.15a Cytochrome P450 (CYP) hepatic enzymes (I) Major CYP enzymes responsible for metabolizing various drugs 1.15b Cytochrome P450 (CYP) ...
... inducing 'non-psychiatric' symptoms 1.14 Drug pharmacokinetics Main pathways of drug metabolism 1.15a Cytochrome P450 (CYP) hepatic enzymes (I) Major CYP enzymes responsible for metabolizing various drugs 1.15b Cytochrome P450 (CYP) ...
Pagina viii
... induce erection Abused substances – opiates Supposed mechanism of dependence, withdrawal symptoms, and treatment options Abused substances – amphetamines (I) Supposed mechanism of dependence, withdrawal symptoms, and treatment options ...
... induce erection Abused substances – opiates Supposed mechanism of dependence, withdrawal symptoms, and treatment options Abused substances – amphetamines (I) Supposed mechanism of dependence, withdrawal symptoms, and treatment options ...
Pagina 3
... induce consequent intracellular changes are termed first messengers. Following their interaction with receptors, they are either metabolized or taken for reuse. Research in recent years has focused on a better understanding of these ...
... induce consequent intracellular changes are termed first messengers. Following their interaction with receptors, they are either metabolized or taken for reuse. Research in recent years has focused on a better understanding of these ...
Pagina 17
... inducing various 'non-psychiatric' symptoms Stimulated/inhibited receptors/transporters Presynaptic Postsynaptic Transporters Agitation Akathisia Dry mouth EPS (c) EPS (p) Headache (c) Headache (p) CNS Hyperthermia Hypothermia Insomnia ...
... inducing various 'non-psychiatric' symptoms Stimulated/inhibited receptors/transporters Presynaptic Postsynaptic Transporters Agitation Akathisia Dry mouth EPS (c) EPS (p) Headache (c) Headache (p) CNS Hyperthermia Hypothermia Insomnia ...
Pagina 22
Je hebt de weergavelimiet voor dit boek bereikt.
Je hebt de weergavelimiet voor dit boek bereikt.
Inhoudsopgave
Chapter 2 Antidepressant drugs and mood stabilizers | 25 |
Chapter 3 Anxiolytic drugs | 67 |
Chapter 4 Antipsychotic drugs | 89 |
Chapter 5 Drugs affecting sexual function | 105 |
Chapter 6 Drugs for the treatment of symptoms related to substance abuse | 115 |
Chapter 7 Miscellaneous drugstreatment modalities | 147 |
Chapter 8 Drug interactions | 161 |
Chapter 9 Treatment strategies evidence based | 207 |
Index | 267 |
Back cover | 275 |
Overige edities - Alles bekijken
Atlas of Psychiatric Pharmacotherapy, Second Edition Roni Shiloh,Rafael Stryjer,Abraham Weizman,David J. Nutt Geen voorbeeld beschikbaar - 2006 |
Veelvoorkomende woorden en zinsdelen
abuse acid action activity acute addition administration adverse agents alcohol alter antagonists antidepressant Antipsychotic drugs APDs associated beneficial benzodiazepines bipolar brain bupropion buspirone capacity carbamazepine cause central chronic citalopram Clin clinical clomipramine clozapine combined concentration consequent considered controlled currently decrease depression disorder dopamine dopaminergic dose effects efficacy enhance enzymes especially established et al evidence factor fluoxetine fluvoxamine function GABA haloperidol improvement increase induce inhibition interactions leading Legend lithium major depressive mania MAOIs mechanism medication metabolism mirtazapine moclobemide Monoamine oxidase mood Name of modality neurons neurotransmitter norepinephrine Notes olanzapine paroxetine pathway patients pharmacokinetic plasma postsynaptic potential presynaptic Psychiatry receptor subtype reduce relatively reported response risk scheme schizophrenia Selective serotonin reuptake serotonergic serotonin reuptake inhibitors sertraline serum levels serum levels/effects severe SGAs shown side-effects significant specific SSRIs Stimulates studies suggest symptoms TCAs therapeutic therapy topiramate toxicity transmission transporter treatment trials Tricyclic valproate various venlafaxine